Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bosutinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC known ✓ | P12931 | 19/20 | 1.00 |
| ▸ | ABL1 known ✓ | P00519 | 5/20 | 1.00 |
| ▸ | BCR known ✓ | P11274 | 4/20 | 1.00 |
| ▸ | LYN known ✓ | P07948 | 1/20 | 1.00 |
| ▸ | HCK known ✓ | P08631 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | ABL2 | P42684 | 2/20 | 1.00 |
| ▸ | WEE2 | P0C1S8 | 2/20 | 1.00 |
| ▸ | WEE1 | P30291 | 2/20 | 1.00 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 1.00 |
| ▸ | STK25 | O00506 | 1/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | RIOK3 | O14730 | 1/20 | 1.00 |
| ▸ | MAP2K7 | O14733 | 1/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | CASK | O14936 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | MAP3K13 | O43283 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bosutinib SCHEMBL19207253 | 1.00 | SRC (1.00) | SRCABL1BCRFYNKCNH2 | |
| Bosutinib SCHEMBL29389315 | 1.00 | SRC (1.00) | SRCABL1BCRFYNKCNH2 | |
| Bosutinib SCHEMBL29428159 | 1.00 | SRC (1.00) | SRCABL1BCRFYNKCNH2 | |
| Bosutinib SCHEMBL29350234 | 1.00 | SRC (1.00) | SRCABL1BCRFYNKCNH2 | |
| Bosutinib SCHEMBL158390 | 1.00 | SRC (1.00) | SRCABL1BCRFYNKCNH2 | |
| Bosutinib SCHEMBL19207270 | 0.98 | SRC (0.97) | SRCABL1BCRFYNKCNH2 | |
| Bosutinib SCHEMBL19207277 | 0.96 | SRC (0.92) | SRCABL1BCRFYNKCNH2 | |
| SCHEMBL676669 | 0.96 | SRC (0.92) | SRCABL1BCRFYNKCNH2 | |
| SCHEMBL30453343 | 0.96 | SRC (0.92) | SRCABL1BCRFYNKCNH2 | |
| SCHEMBL30453317 | 0.96 | SRC (0.92) | SRCABL1BCRFYNKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1902029-B2 | CRYSTALLINE FORMS OF 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-METHOXY-7-[3-(4-METHYL-1-PIPERAZINYL)PROPOXY]-3-QUINOLINECARB-ONITRILE AND METHODS OF PREPARING THE SAME | WYETH LLC (US) | 2022-02-16 | — | — | EP | claimed |
| EP-1902029-B1 | CRYSTALLINE FORMS OF 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-METHOXY-7-[3-(4-METHYL-1-PIPERAZINYL)PROPOXY]-3-QUINOLINECARB-ONITRILE AND METHODS OF PREPARING THE SAME | WYETH LLC (US) | 2014-01-08 | — | — | EP | claimed |
| US-8445496-B2 | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same | WYETH LLC (US) | 2013-05-21 | — | — | US | claimed |
| US-20100324066-A1 | CRYSTALLINE FORMS OF 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-METHOXY-7-[3-(4-METHYL-1-PIPERAZINYL)PROPOXY]-3-QUINOLINECARBONITRILE AND METHODS OF PREPARING THE SAME | WYETH LLC (US) | 2010-12-23 | — | — | US | claimed |
| US-7767678-B2 | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same | WYETH LLC (US) | 2010-08-03 | — | — | US | claimed |
| EP-1902029-A1 | CRYSTALLINE FORMS OF 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-METHOXY-7-[3-(4-METHYL-1-PIPERAZINYL)PROPOXY]-3-QUINOLINECARB-ONITRILE AND METHODS OF PREPARING THE SAME | Wyeth a Corporation of the State of Delaware (US) | 2008-03-26 | — | — | EP | claimed |
| US-20070015767-A1 | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same | WYETH LLC | 2007-01-18 | — | — | US | claimed |
| WO-2007005462-A1 | CRYSTALLINE FORMS OF 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-METHOXY-7-[3-(4-METHYL-1-PIPERAZINYL)PROPOXY]-3-QUINOLINECARB-ONITRILE AND METHODS OF PREPARING THE SAME | WYETH (US) | 2007-01-11 | — | — | WO | claimed |
| EP-4378478-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | Toray Industries, Inc. (JP) | 2024-06-05 | — | — | EP | disclosed |
| CN-111646955-B | Method for preparing bosutinib intermediate | 鲁南制药集团股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-111646940-B | Preparation method of bosutinib intermediate | 鲁南制药集团股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| EP-1902029-B2 | CRYSTALLINE FORMS OF 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-METHOXY-7-[3-(4-METHYL-1-PIPERAZINYL)PROPOXY]-3-QUINOLINECARB-ONITRILE AND METHODS OF PREPARING THE SAME | WYETH LLC (US) | 2022-02-16 | — | — | EP | disclosed |
| CN-111646940-A | Preparation method of bosutinib intermediate | 鲁南制药集团股份有限公司 | 2020-09-11 | — | — | CN | disclosed |
| CN-111646955-A | Method for preparing bosutinib intermediate | 鲁南制药集团股份有限公司 | 2020-09-11 | — | — | CN | disclosed |
| EP-1902029-A1 | CRYSTALLINE FORMS OF 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-METHOXY-7-[3-(4-METHYL-1-PIPERAZINYL)PROPOXY]-3-QUINOLINECARB-ONITRILE AND METHODS OF PREPARING THE SAME | Wyeth a Corporation of the State of Delaware (US) | 2008-03-26 | — | — | EP | disclosed |
| EP-1902029-A1 | CRYSTALLINE FORMS OF 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-METHOXY-7-[3-(4-METHYL-1-PIPERAZINYL)PROPOXY]-3-QUINOLINECARB-ONITRILE AND METHODS OF PREPARING THE SAME | Wyeth a Corporation of the State of Delaware (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20070015767-A1 | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same | WYETH LLC | 2007-01-18 | — | — | US | disclosed |
| US-20070015767-A1 | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same | WYETH LLC | 2007-01-18 | — | — | US | disclosed |
| WO-2007005462-A1 | CRYSTALLINE FORMS OF 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-METHOXY-7-[3-(4-METHYL-1-PIPERAZINYL)PROPOXY]-3-QUINOLINECARB-ONITRILE AND METHODS OF PREPARING THE SAME | WYETH (US) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007005462-A1 | CRYSTALLINE FORMS OF 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-METHOXY-7-[3-(4-METHYL-1-PIPERAZINYL)PROPOXY]-3-QUINOLINECARB-ONITRILE AND METHODS OF PREPARING THE SAME | WYETH (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015767-A1 | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same | NT5C, KDM4C, TUBA3C | SRC 2568/4885ABL1 160/4885BCR 3005/4885 |
| US-20100324066-A1 | CRYSTALLINE FORMS OF 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-METHOXY-7-[3-(4-METHYL-1-PIPERAZINYL)PROPOXY]-3-QUINOLINECARBONITRILE AND METHODS OF PREPARING THE SAME | NT5C, KDM4C, TUBA3C | SRC 2568/4885ABL1 160/4885BCR 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.